Insider Selling: Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Insider Sells $155,600.00 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the business’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $15.56, for a total transaction of $155,600.00. Following the completion of the sale, the insider directly owned 122,279 shares in the company, valued at approximately $1,902,661.24. This represents a 7.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Centessa Pharmaceuticals Price Performance

Shares of CNTA opened at $15.41 on Monday. The firm has a market cap of $2.06 billion, a PE ratio of -8.51 and a beta of 1.45. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $9.10 and a 52-week high of $19.09. The business’s 50 day moving average price is $13.55 and its two-hundred day moving average price is $14.38. The company has a debt-to-equity ratio of 0.28, a quick ratio of 14.37 and a current ratio of 14.37.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.15. On average, equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its position in Centessa Pharmaceuticals by 40.1% in the 4th quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company’s stock valued at $3,189,000 after buying an additional 54,482 shares in the last quarter. GAMMA Investing LLC grew its stake in Centessa Pharmaceuticals by 1,509.6% in the first quarter. GAMMA Investing LLC now owns 61,762 shares of the company’s stock valued at $888,000 after acquiring an additional 57,925 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $162,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth approximately $171,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth approximately $1,225,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analysts Set New Price Targets

CNTA has been the topic of several recent research reports. Needham & Company LLC assumed coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a “buy” rating and a $35.00 target price on the stock. Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Chardan Capital assumed coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued a “buy” rating and a $30.00 price objective on the stock. Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an “overweight” rating and a $38.00 target price for the company. Finally, Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They set an “outperform” rating and a $6.00 price target for the company. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $28.10.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.